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CONSPECTUS
Metal–organic frameworks (MOFs), a class of hybrid materials formed by the self-assembly of
polydentate bridging ligands and metal-connecting points, have been studied for a variety of
applications. Recently, these materials have been scaled down to nanometer sizes, and this
Account details the development of nanoscale metal–organic frameworks (NMOFs) for
biomedical applications. NMOFs possess several potential advantages over conventional
nanomedicines such as their structural and chemical diversity, their high loading capacity, and
their intrinsic biodegradability. Under relatively mild conditions, NMOFs can be obtained as
either crystalline or amorphous materials. The particle composition, size, and morphology can be
easily tuned to optimize the final particle properties. Researchers have employed two general
strategies to deliver active agents using NMOFs: by incorporating active agents into the
frameworks or by loading active agents into the pores and channels of the NMOFs. The
modification of NMOF surfaces with either silica coatings or organic polymers improves NMOF
stability, fine-tunes their properties, and imparts additional functionality.
Preliminary biomedical applications of NMOFs have focused on their use as delivery vehicles for
imaging contrast agents and molecular therapeutics. Because NMOFs can carry large amounts of
paramagnetic metal ions, they have been extensively explored as magnetic resonance imaging
(MRI) contrast agents. Both Gd3+- and Mn2+-containing NMOFs have shown excellent efficacy as
T1-weighted contrast agents with large per metal- and per particle-based MR relaxivities. Fe3+-
containing NMOFs have demonstrated excellent T2-weighted contrast enhancement. Upon
intravenous injection of iron carboxylate NMOFs in Wistar rats, researchers observed negative
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signal enhancement in the liver and spleen, which dissipated over time, indicating the degradation
and clearance of the NMOF. Through the incorporation of luminescent or high Z element building
blocks, NMOFs have also served as viable contrast agents for optical imaging or X-ray computed
tomography (CT) imaging. Incorporation of membrane impermeable dyes into NMOFs allowed
for their uptake by cancer cells and for their controlled release as the framework decomposed.
NMOFs have been used to deliver anticancer drugs and other chemotherapeutics. Cisplatin
prodrugs were incorporated within NMOFs at exceptionally high levels, either through use of the
prodrug as the building block or through attachment of the prodrug onto the framework after
synthesis. These NMOFs were encapsulated within a silica shell and targeted to cancer cells. In
vitro assays revealed that the targeted NMOFs possessed similar efficacy to cisplatin, while the
nontargeted NMOFs were less active. Several different therapeutic molecules were loaded within
porous iron-carboxylate NMOFs at unprecedented levels. The NMOF showed sustained drug
release with no burst effect, and in vitro assays revealed that the nanoencapsulated drug possessed
similar efficacy to the free drug. Although still at a very early stage of development, NMOFs have
already shown great promise as a novel platform for nanomedicine. The compositional tunability
and mild synthetic conditions used to produce NMOFs should allow for the incorporation of other
imaging and therapeutic agents and their effective delivery to targeted cells in vivo.
Introduction
Metal–organic frameworks (MOFs), also called coordination polymers or coordination
networks, are a class of hybrid materials formed by the self-assembly of metal ions or
clusters and polydentate bridging ligands typically under mild conditions. Due to virtually
limitless combinations of metals and ligands, the physicochemical properties of MOFs can
be judiciously tuned for specific applications. As a result, bulk phase MOFs have shown
promise for a number of diverse applications including gas storage,1,2 catalysis,3–5 nonlinear
optics,6 separations,7,8 sensing,9,10 and light-harvesting.11 Because MOFs can exhibit
exceptionally high surface areas with large pore sizes, they have also been investigated for
applications in loading and controlled release of several drug molecules.12–14 However,
MOFs need to be scaled down to the nanoregime to form nanoscale metal–organic
frameworks (NMOFs) for use as delivery vehicles for imaging agents and drug molecules.
We and others have recently shown that NMOFs can be synthesized using a variety of
different techniques that have been developed for inorganic and organic polymeric
nanoparticles. NMOFs not only maintain the structural diversity and physicochemical
properties as bulk MOFs but also exhibit particle dimensions in the tens to hundreds of
nanometers range, making them potential nanocarriers for imaging agents and drug
molecules.15–17
Although a large number of materials have been developed as nanocarriers for imaging and
therapuetic agents,18–21 the majority of them can be categorized into either purely inorganic
(such as quantum dots, Fe3O4, and Au nanoparticles) or purely organic (such as liposomes,
dendrimers, polymers). Each of these classes of nanomaterials has its own strengths and
weaknesses. NMOFs possess some potential advantages over existing nanocarriers. First,
MOFs are compositionally and structurally diverse, allowing for the facile synthesis of
NMOFs of different compositions, shapes, sizes, and chemical properties. Second, NMOFs
are intrinsically biodegradable as a result of relatively labile metal–ligand bonds, making it
possible to rapidly degrade and clear the nanocarriers after the intended task is completed. In
this Account, we intend to summarize recent advances in the development of NMOFs as
delivery vehicles for imaging agents and molecular therapeutics. More specialized reviews
focusing on the synthesis of NMOFs15,16 and the use of NMOFs in biomedical imaging22
and in drug delivery23 have recently appeared.
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Synthesis of Nanoscale Metal–Organic Frameworks
As the synthesis of nanoscale and microscale MOFs has recently been reviewed,15,16 we
only outline general synthetic strategies here with specific examples of the synthesis of
biomedically relevant NMOFs. Four general methods have been utilized to synthesize
NMOFs: nanoprecipitation, solvothermal, reverse microemulsion, and surfactant-templated
solvothermal reactions. The first method tends to yield amorphous materials, while the latter
three methods can afford crystalline materials, owing to the ability to exert a better control
on nanoparticle nucleation and growth kinetics. The first two methods are surfactant-free,
whereas the last two methods rely on surfactants not only to control the particle synthesis
but also to stabilize these particles.
In a typical NMOF synthesis, precursor solutions are mixed together to allow particle
nucleation and growth (Figure 1a). In the nanoprecipitation method, nanoparticles form
because the particles are insoluble in the solvent system whereas the individual precursors
remain soluble. This strategy was used to synthesize NMOFs composed of the anticancer
prodrug c,c,t-Pt(NH3)2Cl2(succinate)2 (DSCP) and Tb3+ (1).24 In this synthesis, the pH
value of an aqueous solution of TbCl3 and [NMeH3]2DSCP was adjusted to 5.5 with
aqueous sodium hydroxide. Methanol was then quickly added to the precursor solution,
leading to the instantaneous formation of 1 which were shown by SEM and DLS to adopt a
spherical morphology with a diameter of 50–60 nm (Figure 1b). 1 contains 75 wt % of the
DSCP prodrug; such a high loading of cisplatin has not been achieved using other
nanocarriers.26,27
Solvothermal synthesis of NMOFs can be achieved with either conventional heating or a
microwave. Because high reaction temperatures are involved in the solvothermal method,
more extensive transformations of the precursors typically occur before the formation of the
NMOF nanoparticles. Temperatures and heating rates provide additional parameters to
control the NMOF particle nucleation and growth. For example, Fe3+ NMOF particles with
the formula of Fe3(μ3-O)Cl(H2O)(BDC)3 (2) were synthesized by heating an equimolar
solution of FeCl3 and terephthalic acid (BDC) with a microwave.25 2 displayed an
octahedral morphology with an average diameter of 200 nm (Figure 1c). PXRD studies
showed that 2 was highly crystalline and adopted the known MIL-101 structure. 2 could also
be modified by incorporating a fraction of 2-aminoterephallic acid (NH2–BDC) to form 2a
particles that provided an orthogonal amino group for further functionalization. 2a retained
the MIL-101 structure with up to 17.5 mol % of NH2–BDC incorporation, while the
particles synthesized with higher amounts of NH2–BDC adopted the nonporous MIL-88B
structure.
Surfactant-assisted synthesis of NMOFs can be carried out at room temperature or at
elevated temperatures. Because the building blocks for NMOFs are typically water-soluble,
reverse microemulsions provide another method to control the nucleation and growth
kinetics of NMOF particles. Reverse microemulsions are formed by using surfactants to
stabilize water droplets within a nonpolar organic phase (Figure 2a). This method was used
to synthesize crystalline Gd(BDC)1.5(H2O)2 (3) nanorods (Figure 2b).28 Two separate
microemulsions containing either GdCl3 or [NMeH3]2[BDC] were mixed and allowed to
react for a given amount of time. The particle morphologies could be controlled by adjusting
the w value (water to surfactant molar ratio) of the micro-emulsion. 3 synthesized at w = 10
was 1–2 μm in length and 100 nm in diameter. Nanorods of 100–125 nm in length and 40
nm in diameter were obtained when the w value was decreased to 5. Gd(BTC)(H2O)3 (4,
BTC = benzene-1,2,4-tricarboxylate) nanoplates of ~100 nm in diameter and ~ 35 nm in
thickness were also synthesized by this method. Both 3 and 4 were crystalline and matched
known lanthanide-carboxylate bulk phases.
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Surfactant molecules can also be used to template the NMOF synthesis under solvothermal
conditions (Figure 2a) by coating the surfaces of growing NMOF particles. Surfactant
molecules play an important role in defining NMOF morphologies. For example, Gd-BHC
NMOFs (BHC = benzene hexacarboxylic acid) were synthesized by a surfactant templated
solvothermal method.29 A reverse microemulsion of GdCl3 and [NMeH3]6[BHC] was
transferred to a Parr reactor and heated at 120 °C. The resulting NMOF had the formula
Gd2(BHC)(H2O)6 (5) and exhibited a blocklike morphology with dimensions of 25 × 50 ×
100 nm3 (Figure 2c). 5 was crystalline and matched a previously reported lanthanide-BHC
phase. The compositions and morphologies of Gd-BHC NMOFs were also shown to be
sensitive to the pH values of the reaction system. MOF microparticles of a different
composition were obtained when the reaction was carried out at lower pH.29
The four general methods described above have been adopted to synthesize a large number
of NMOFs. With the ability to independently adjust NMOF precursors, reaction solvents,
pH values, temperatures, surfactant or other templating molecules, w values, and other
parameters, a range of NMOFs with well-defined compositions and morphologies have been
synthesized. It has also been shown that surface termination can be an important parameter
in defining NMOF morphologies.30,31 Although the synthesis of NMOFs has been
phenomenologically described, there is little study on the NMOF growth mechanism and
kinetics. Fundamental understanding of NMOF growth mechanism and kinetics will
facilitate the development of NMOFs as a promising class of hybrid nanomaterials for
biological and biomedical applications.
Strategies to Incorporate Biomedically Relevant Agents within NMOFs
Several different methods have been developed to incorporate imaging and therapeutic
agents into NMOFs by taking advantage of the tailorability of NMOFs to afford very high
agent loadings. These loading methods fall into two general categories: direct incorporation
during NMOF synthesis or postsynthesis loading (Figure 3). A combination of these two
strategies can also be used to load different agents into NMOFs to allow the development of
multimodal imaging agents or theranostic nanoparticles.
In the direct incorporation strategy, biomedically relevant agents are used as either the metal
connecting points28–30,32 or the bridging ligand to assemble NMOFs (Figure 3a).24,33,34
Paramagnetic metal ions such as Gd3+, Fe3+, and Mn2+ not only link the ligands to form the
NMOFs but also act as magnetic resonance imaging (MRI) contrast enhancement agents
either in intact NMOF particles or upon dissolution of NMOF particles (Table 1). DSCP and
I4–BDC were used to bridge metal centers to form NMOFs to provide the anticancer
therapeutic cisplatin or the high Z element iodine for CT imaging, respectively.24,33 The
direct incorporation strategy has the ability to achieve very high agent loadings with uniform
distribution throughout the nanoparticle, but the morphology and physicochemical
properties of these NMOFs need to be individually tuned. Care must also be taken to ensure
that the agent is not altered or degraded during the NMOF synthesis. The direct
incorporation strategy can be modified to include a small amount of the biomedically
relevant agent during the synthesis as a dopant, imparting additional functionality to the
NMOF (Table 1). This method has been used to encapsulate a number of different agents
with various properties such as optical dyes, chemotherapeutics, proteins, and smaller
nanoparticles.35–41 However, only a low drug loading can be achieved by this method and
the release kinetics of the agent from the NMOF may be very different than the framework
decomposition rate.
In the postsynthesis loading strategy, biomedically relevant agents are loaded into the
NMOF pores. After the synthesis of highly porous NMOFs, the active agent is incorporated
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within the NMOF by noncovalent (Figure 3b1) or covalent interactions (Figure 3b2).
Noncovalent drug loading was first demonstrated using bulk phase MOFs,12–14 achieving
impressive loading of up to 1.4 g of ibuprofen/g of MOF.12 Release studies showed very
slow, sustained drug release from the framework with minimal burst effects. More recent
studies have extended this strategy to NMOFs which have been loaded with hydrophilic,
amphiphillic, and hydrophobic drugs.30 The NMOF pore size must be larger than the
encapsulated agent to afford high loadings.
Since noncovalent drug loading is an inherently reversible process, subsequent processing of
the NMOF may lead to premature release of the agent. Postsynthesis covalent attachment of
the agent offers a more robust approach, as the agent will only be released when the NMOF
decomposes. In this method, orthogonal functional groups within the frameworks of porous
NMOFs are used to covalently attach active agents.25,42 This strategy effectively creates a
prodrug, so it is essential that the functionality of the agent is maintained. The active drug
must be cleavable from the NMOF under specific biological conditions. As functional
groups at or near the surface of the nanoparticle are kinetically more accessible, agent
loading might not be uniform throughout the NMOF particles. As an example, NMOF 2a
possessed NH2–BDC groups, which were used to attach either an optical contrast agent or a
chemotherapeutic through covalent bonds.25
Surface Modification of NMOFs
As-synthesized nanomaterials typically need to be further functionalized to optimize their in
vivo performance. Surface modification is a commonly used strategy for improving water
dispersity, reducing plasma protein binding, avoiding the reticuloendothelial system, and
adding affinity molecules to target specific cells or tissues.43 Surface modification is
particularly important for NMOFs because of the intrinsic instability of many NMOFs under
physiological conditions; surface coatings can slow down the degradation of NMOFs and
thus prevent premature release of cargoes. Two general strategies have been used to modify
the NMOF surfaces: silica encapsulation and coating with organic polymers (Figure 4).
Other surface functionalization approaches need to be explored to further optimize the in
vivo performance of many NMOFs.
Lin and co-workers first stabilized NMOFs by encapsulating them within a silica shell.
Silica coatings have been extensively used to modify inorganic and polymer
nanoparticles.44,45 A silica shell offers several advantages as a surface coating, including
biocompatibility, increased water dispersibility, and easy functionalization with silyl-derived
molecules. Generally, NMOFs are first coated with a hydrophilic polymer, such as
polyvinylpyrrolidone (PVP), to keep the NMOF particles well dispersed so that individual
NMOF particles (but not aggregates) are coated with silica shells. For example, NMOF 3
was first coated with PVP and then treated with tetraethylorthosilicate (TEOS) in basic
ethanol to afford 3@silica core–shell nanostrcutures.46 The silica shell thickness can be
controlled by adjusting the reaction time or reactant concentrations. Release profile
experiments demonstrated that a silica shell significantly slows down the rate of NMOF
dissolution and Gd release, and the kinetics of Gd3+ release depends on the silica shell
thickness. This method was also used to coat Tb3+- and Mn2+-carboxylate NMOFs.24,32 2a
was coated with silica by an alternative method using sodium silicate as the silica source as
iron-carboxylate NMOFs are unstable under basic conditions.25 The surface of these core–
shell NMOFs can be further modified by grafting a silyl-derived molecule onto the silica
shell through surface silanol groups to impart additional functionality.24,25,32,46 For
example, RGD-targeted 1 increased its anticancer efficacy against human colon cancer cells
compared to the untargeted 1.24
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Subsequent studies have modified the surface of NMOFs with organic polymers (Figure 4)
as a way to enhance biocompatibility and retard framework decomposition.30,47–49 The
polymers must possess an end group that can bind to the NMOF through either vacant metal
coordination sites, electrostatic attraction to the particle surface, or covalent attachment to
the bridging ligand. Polymers can be added either during NMOF synthesis or
postsynthetically. A number of different polymers were conjugated to 3 through the thiol
end groups of the polymers which bind to vacant Gd3+ coordination sites.47,48 The polymer
coatings slow down the release of Gd3+ ions. Additional functional groups on the polymer
allowed for the incorporation of chemotherapeutics, optical imaging agents, and targeting
agents. Polymer modification also altered the properties of 3 as a MRI contrast agent. Lin
and co-workers modified the surface of several NMOFs with PVP to stabilize the NMOF
and increase its dispersibility as a way to increase the efficiency of a subsequent silica
coating step.24,32,46 As a large inventory of polymers are available for biomedical
applications, surface modification with polymers imparts additional tunability to optimize
the performance of polymer coated NMOFs.
Biomedical Applications of NMOFs
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) is a noninvasive imaging technique based on the
detection of nuclear spin reorientations in a magnetic field. MRI provides excellent spatial
resolution, high soft tissue contrast, and large penetration depth. However, MRI is
intrinsically insensitive and generally used for the detection of water protons which are
present in high molar concentrations in biological specimens.50 Large doses of contrast
enhancement agents, typically small-molecule Gd chelates, are used in approximately 35%
of all clinical scans to enhance the contrast between normal and diseased tissues.51 Gd
chelates provide T1-weighted, or positive, signal enhancement. Superparamagnetic materials
such iron oxide nanoparticles are clinically used for T2-weighted or negative signal
enhancement.52 The effectiveness of a MRI contrast agent is expressed by the relaxivity
value (r1 for positive enhancement and r2 for negative enhancement), with agents possessing
large relaxivities providing more effective contrast.
The effectiveness of Gd3+-containing NMOFs as T1-weighted contrast agents was first
demonstrated by Lin and co-workers who showed that 3 and 4 possessed r1 values about an
order of magnitude higher than that of Omniscan, a clinically used small molecule contrast
agent, at 3T (Figure 5, Table 2).28 A number of other studies have been published since,
supporting the finding that Gd3+-containing NMOFs can exhibit extraordinarily high MR
relaxivities.28,29,39,47,48,53,54 Many of the Gd3+-containing NMOFs could also act as T2-
weighted contrast agents, which is not possible using small molecule Gd chelates (Figure 5
and Table 2). As previously mentioned, the size and aspect ratio of 3 could be manipulated
by changing the w value of the microemulsion. The relaxivity values of the nanoparticles
showed an inverse dependence on nanoparticle size, with the smaller nanoparticles
possessing larger r1 relaxivity. It was believed that smaller nanoparticles have higher surface
to volume ratios, which enhanced the exchange between Gd3+ bound water and bulk water,
leading to higher relaxivities. This size dependent trend on relaxivity was also observed in
Gd3+-containing NMOFs synthesized by Kimizuka and co-workers.39 Boyes and co-workers
were able to tune the relaxivity of 3 by polymer surface modification.47,48 Hydrophilic
polymers led to an increased r1 relaxivity, while hydrophobic polymers increased the r2
relaxivity compared to the unmodified nanoparticle. The differences in relaxivities were
explained by increased or decreased polymer water retention.
As the toxicity of Gd3+ ions is now well established,55 the in vivo utility of Gd3+-containing
NMOFs is uncertain. Lin and co-workers have developed Mn-based NMOFs for T1-
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weighted contrast enhancement.32 Mn2+ ions have been shown to be potent MRI contrast
agents with lower toxicity than free Gd3+.56,57 Reaction of Mn2+ with BDC led to nanorods
of Mn(BDC)(H2O)2 (6), which were 50–100 nm in diameter and up to several micrometers
in length. Blocklike nanoparticles of Mn3(iBTC)2(H2O)6 (7, iBTC = 1,3,5-benzene-
tricarboxylic acid) of 50–300 nm in diameter were obtained when iBTC was used in place of
BDC. The NMOFs showed modest r1 relaxivity (Table 2), but acted as reservoirs to
selectively release large doses of Mn2+ ions to achieve T1-weighted signal enhancement. 7
was coated with a thin silica shell and functionalized with a cancer targeting peptide. MRI
demonstrated increased uptake of the targeted nanoparticle, which was confirmed by
confocal microscopy and ICP-MS studies (Figure 6). 7 was evaluated in vivo and
demonstrated T1-weighted signal enhancement in the liver, spleen, and aorta 1 h after
injection. This signal enhancement was believed to result from the Mn2+ ions released from
the NMOF.
Horcajada and co-workers synthesized a series of iron-carboxylate NMOFs as T2-weighted
contrast agents.30 These crystalline NMOFs ranged in size from 50 to 350 nm, matching
known bulk phase materials of MIL-89 (8), MIL-88A (9), MIL-100(10), MIL-101-NH2(11),
MIL-88Bt (12), and MIL-53 (13). Pegylated versions of 9 (PEG-9) and 10 (PEG-10) were
also synthesized. 9, PEG-9, 10, and PEG-10 showed high r2 relaxivity (Table 2) on a per
metal basis. 9 was evaluated in Wistar rats (Figure 7). Negative enhancement of the liver
and spleen was observed after injection of 9, which dissipated 3 months postinjection,
indicating the accumulation, degradation, and clearance of 9. Iron oxide nanoparticles have
also been encapsulated within other NMOFs as guest species.35,58
Optical Imaging
Optical imaging is widely used in biological studies. Typically visible light is used to excite
dye molecules within a tissue, which fluoresce at longer wavelengths. This technique is
ubiquitous for in vitro and ex vivo studies but is limited by poor tissue penetration in in vivo
applications.59 A number of NMOFs have been synthesized which are inherently
luminescent, but have not been evaluated as biomedical imaging agents.28,29,39,60–63 The
luminescence of these NMOFs is not ideal for biomedical imaging applications due to its
nonoptimum absorption properties and low quantum yields. Lin and co-workers were able to
create NMOFs containing a phosphorescent Ru(bpy)32+ derivative as the bridging ligand
and Zn2+ (14) or Zr4+ (15) metal connecting points (Figure 8).64 15 was coated with a layer
of amorphous silica, functionalized with PEG, and targeted to cancer cells. Confocal
microscopy studies using human lung cancer cells demonstrated increased uptake of the
targeted nanoparticles (Figure 8), which was confirmed by ICP-MS analysis.
In some cases, the optical dye was incorporated within the framework either
postsynthetically or as a guest species.25,35,37,39–41,60 For example, silica coated 7 was
modified with both a fluororophore and targeting peptide.32 Confocal microscopy showed
increased uptake of the targeted particle by cancer cells, confirming the MR imaging results
(Figure 6b–d). Lin and co-workers functionalized 2a with a Bodipy-based fluorophore
(Bodipy-2a) at 5.6–11.7 wt % loadings.25 Intact Bodipy-2a was not fluorescent due to iron
quenching, but it exhibited strong fluorescence upon NMOF decomposition. Confocal
microscopy of silica coated Bodipy-2a showed dose dependent cellular localization and
fluorescence. Boyes and co-workers modified the surface of 3 with a PNIPAM-co-PNAOS-
co-PFMA copolymer (3a).48 This polymer contained fluorescein and a succinimide group
for further functionalization. 3a was targeted to cancer cells and its uptake in canine FITZ-
HSA cells was investigated by fluorescence microscopy. The targeted nanoparticle showed
cellular localization after 1 h of incubation and cellular internalization after 24 h, while
untargeted 3a did not show any localization or uptake. Kimizuka and co-workers created a
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series of NMOFs based on lanthanide ions and nucleotides.37–39,60,65 Anionic dyes, such as
perylene-3,4,9,10-tertacarboxylate, were incorporated within NMOFs of adenosine 5′-
monophosphate and Gd3+ (perylene-16). Confocal microscopy showed the uptake of
perylene-16 into the lysosomes of HeLa cells and its biodistribution was studied in a murine
model. Ex vivo analysis showed that perylene-16 accumulated and remained in the liver for
up to 48 h post-injection, with no fluorescence observed in the kidneys, lungs, or spleen.
Lanthanide-nucleotide NMOFs were used to successfully encapsulate other anionic dyes and
negatively charged quantum dots as well.37–39
X-ray Computed Tomography (CT) Imaging
CT imaging is based on specimen attenuation of X-rays and can provide 3D images with
excellent spatial resolution.66,67 High Z number elements such as iodine, barium, and
bismuth are typically used as CT contrast agents; however, they must be administered in
large doses (tens of grams) to achieve adequate contrast. A nanoparticle platform can thus
provide superior contrast enhancement. Lin and co-workers constructed NMOFs containing
I4–BDC and either Cu2+(17) or Zn2+ (18).33 CT phantom studies showed that both
nanoparticles possessed slightly higher X-ray attenuation factors than iodixanol, a
commercially used contrast agent (Figure 9). The higher nanoparticle attenuation results
from the contributions of the metal centers. NMOFs should provide an interesting platform
for incorporating other high Z elements for CT imaging.
Drug Delivery
Current small molecule drugs are often limited by their nonspecific distribution throughout
the body, leading to high doses, rapid clearance, poor pharmacokinetics, and high side
effects. Many of these drawbacks can be alleviated through the use of nanoparticulate
formulations. Nanoparticles often possess superior pharmacokinetic profiles, so
incorporating a drug within a nanoparticle can lead to improved efficacy. The clinical
success of nanoparticle therapeutics such as Doxil and Abraxane illustrate the power of this
approach, and many other nanoparticle-based therapeutics have shown promise in clinical
trials.18 Lin and co-workers have developed two NMOF platforms to deliver cisplatin-based
chemotherapeutics.24,25 NMOF-1 was built from a cisplatin prodrug DSCP and Tb3+ ions
using a nanoprecipitation procedure. 1 was coated with a thin layer of silica (1a) and
targeted with a silyl-derived peptide (1b) to cancer cells. When 1a is placed in physiological
medium, the framework decomposes and the cisplatin prodrug diffuses through the silica
shell in a controlled manner (Figure 10a). 1b possessed similar cytotoxicity against human
colon cancer cells as cisplatin, while 1 and 1a were less effective, presumably due to
increased uptake of 1b via receptor mediated endocytosis. Iron(III)-carboxylate NMOF 2a
was also postsynthetically modified to contain a cisplatin prodrug, c,c,t-
Pt(NH3)2Cl2(succinate)(OEt) (cisplatin-2a, Figure 10b).25 Silica-coated cisplatin-2a with a
RGD peptide targeting ligand demonstrated comparable cytotoxicity to cisplatin in vitro. 3a
could also be modified to contain methotrexate, which showed similar cytotoxicity against
FITZ-HSA cells to the free methotrexate.48
Horcajada and co-workers encapsulated a number of therapeutics within the iron-
carboxylate NMOFs 8–11 and 13.30 These synthesized NMOFs were soaked in drug
solutions for loading. The anticancer drug busulfan could be loaded into 9 at 5 times the
loading of previously reported systems. In vitro cytotoxicity assays showed that busulfan-
loaded 9 possessed the same activity as the free drug against several cell lines. 9 was also
loaded with triphosphorylated azidothymidine, an anti-HIV drug. In vitro assays showed that
loaded 9 possessed significant anti-HIV activity. Maspoch and co-workers encapsulated
several anticancer drugs as guest species within NMOFs synthesized from Zn2+ and 1,4-
bis(imidazol-1-ylmethyl)benzene (19).36 These drugs were encapsulated within 19 with
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modest efficiency (≈20 wt %) and showed fast drug release. In vitro assays performed with
doxorubicin-loaded 19 showed comparable cytotoxicity to that of free doxorubicin. Iron
carboxylate NMOFs such as 2a, 3a, and 8–13 possess considerable potential to act as
theranostic agents, as these NMOFs were utilized as both imaging contrast and drug delivery
agents;25,30 further work is needed to demonstrate the real-time monitoring of drug uptake
and treatment efficacy.
Conclusions and Future Outlook
The development of NMOFs as biomedical imaging and drug delivery agents is in its
infancy when compared to other nanocarriers. Nonetheless, NMOFs have already shown
great promise as a new nanocarrier platform owing to the structural and chemical diversity,
mild synthetic conditions, and the ability to carry a diverse array of imaging and therapeutic
agents in unprecedentedly high loadings. We foresee that many other imaging agents and
drugs will be incorporated into NMOFs in the future by taking advantage of the totally
tunable nature of NMOFs. Particularly, combining both imaging and therapeutic agents in
the same NMOF platform should greatly facilitate the efficacy studies of this promising
class of theranostic nanoparticles. NMOFs also need to be further refined by using
biocompatible components and by achieving more effective surface functionalization to
ensure prolonged blood circulation, evasion of the RES system, and better tissue specificity.
Although there have been considerable amounts of in vitro efficacy studies on NMOFs, no
systematic investigation of in vivo efficacy has been launched yet. Such systematic in vivo
studies are needed in order to optimize the performance of NMOFs. Optimized NMOFs
should have a bright future in biomedical imaging and drug delivery.
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(a) Surfactant-free synthesis of NMOFs by simply mixing NMOF precursors in appropriate
solvents. In the nanoprecipitation method, the NMOF forms rapidly at r.t., whereas in the
solvothermal method heating the solution leads to more controlled NMOF particle growth.
(b, c) SEM images of (b) amorphous NMOF 124 and (c) crystalline NMOF 2.25
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(a) Surfactant-templated NMOF synthesis, either based on reverse microemulsions at r.t. or
based on surfactant-assisted solvothermal reactions. (b, c) SEM images of crystalline
particles (b) 328 and (c) 5,29 respectively.
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Schematics showing the strategies for incorporating biomedcially relevant agents into
NMOFs. (a) Direct incorporation of biomedically relevant metal connecting points or
bridging ligands. (b1) Postsynthesis encapsulation via noncovalent interactions. (b2)
Postsynthesis incorporation via covalent attachment.
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Schematic showing surface functionalization of crystalline and amorphous NMOFs with
either a thin shell of silica or with polymer coatings. TEM images of representative silica-
and PVP-coated NMOFs are also shown. Reproduced with permission from refs 24 and 46.
Copyright 2008 and 2007 American Chemical Society.
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Left: T1-weighted MR phantoms of 3 in water with 0.1% xanthan gum at 3T. Right: r1 and
r2 relaxivity curves of 3 of ~100 nm in length by ~ 40 nm in diameter. Reproduced with
permission from ref 28. Copyright 2006 American Chemical Society.
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(a) In vitro MR images of HT-29 cells incubated with 7@silica (left), nontargeted 7@silica
(middle), and c(RGDfK)-targeted 7@silica (right). Confocal images of HT-29 cells
incubated with no particle (b) nontargeted 7@silica (c), and c(RGDfK)-targeted 7@silica
(d). The cell nuclei were stained with DRAQ5 (blue), and the particles were detected with
rhodamine B (green). Scale bars represent 20 μm. Reproduced with permission from ref 32.
Copyright 2008 American Chemical Society.
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T2 weighted MR images of Wistar rats injected with no particle (a,c,e) or 220 mg/kg 9
(e,d,f). The images were acquired using either gradient echo (a,b,e,f) or spin echo (c,d)
sequences. The images show the liver (a–d) or spleen (e,f) regions 30 min postinjection. [dm
= dorsal muscle, k = kidney, li = liver, s = spleen, st = stomach]. Reproduced with
permission from ref 30. Copyright 2010 Nature Publishing Group.
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Left: SEM image of anisamide-targeted and silica-coated particles of 15. The inset shows
the schematic of such core–shell nanoparticles. Right: Confocal microscopy image of H460
cell after incubated with anisamide-targeted and silica-coated particles of 15. Reproduced
with permission from ref 64. Copyright 2011 John Wiley and Sons.
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CT phantom images of 17 (a), 18 (b), and iodixanol (c). 17 and 18 were dispersed in ethanol,
and iodixanol was dissolved in water. From the top, clockwise, the slots have [I] = 0, 0.075,
0.150, 0.225, and 0.300 M. (d) X-ray attenuation as a function of [I] for 17 at 40 kVp, 18 at
50 kVp, and iodixanol at 40 kVp. Reproduced with permission from ref 33. Copyright 2009
John Wiley and Sons.
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Schematic representations of the synthesis, modification, and cisplatin release from 1 (a) and
2a (b). The cisplatin prodrug was loaded into 1 by direct incorporation (a) or into 2 by
postsynthesis covalent attachment (b). Reproduced with permission from refs 24 and 25.
Copyright 2008 and 2009 American Chemical Society.
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TABLE 2
MR Relaxivity Values of NMOFs on a per Metal Basisa
NMOF (dimensions) field strength r1 (mM−1s−1) r2 (mM−1s−1)
3 (100 × 400 nm)28 3T 35.8 55.6
3 (400 × 700 nm)28 3T 26.9 49.1
3 (1000 × 100 nm)28 3T 20.1 45.7
4 (100 × 25 nm)28 3T 13.0 29.4
Omniscan28 3T 4.1
6 (50–100 × 750–3000 nm)32 3T 5.5 80.0
7 (50–300 nm)32 3T 7.8 70.8
7 (50–300 nm)32 9.4T 4.6 141.2
7@silica (50–300 nm)32 9.4T 4.0 112.8
9 (150 nm)30 9.4T 56
PEG-9 (150 nm)30 9.4T 95
10 (200 nm)30 9.4T 73
PEG-10 (200 nm)30 9.4T 92
a
Omniscan is a clinically used small molecule Gd complex.
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